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ABSTRACT. This paper describes how investigators may design, conduct, and report economic 
evaluations of pharmacotherapy for pain and symptom management. Because economic evalua­
tion of therapeutic interventions is becoming increasingly important, there is a need for guidance 
on how economic evaluations can be optimally conducted. The steps required to conduct an eco­
nomic evaluation are described to provide this guidance. Economic evaluations require two or 
more therapeutic interventions to be compared in relation to costs and effects. There are five types 
of economic evaluations, based on analysis of: (1) cost-effectiveness, (2) cost-utility, (3) cost- 
minimization, (4) cost-consequence, and (5) cost-benefit analyses. The six required steps are: 
identify the perspective of the study; identify the alternatives that will be compared; identify the 
relevant costs and effects; determine how to collect the cost and effect data; determine how to per­
form calculation for cost and effects data; and determine the manner in which to depict the results 
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insured because of the implementation of 
Medicare and Medicaid.
The cost of heal thcare increased in the 1970s 
and 1980s as a result of fee-for-service payment 
structure and growth in healthcare service utili­
zation. Private insurers, most notably Blue 
Cross and Blue Shield plans, also increased 
through employers for hospital and physician 
services. The rise in healthcare spending rose
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BACKGROUND AND HISTORY
Recent history has seen great increases in ex­
penditures and rises in healthcare services. The 
1950s and 1960s were a period of massive ex­
pansion in the number of healthcare facilities, 
schools and trai ning programs, and advances in 
healthcare technology. Concurrently there was 
an increase in the number of Americans being
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uations actually fall into on e o f  the partial 
evaluation boxes.
WHEN IS A FORMAL ANALYSIS 
NEEDED?
Formal analyses arc not a lw ays needed. B e­
fore conducting any eco n o m ic  analysis o f  a 
healthcare tech n ology , program, or service, the 
investigator must first determ ine whether the 
analysis is needed. For exam ple, as depicted in 
the Figure 2, i f  the cost o f  a new  drug is low er  
and the drug is more e ffec tiv e  than current ther­
apy, or v ice-versa, no pharm acoeconom ic anal­
ysis is indicated. T he ch o ice  o f  therapy is o b v i­
ous as represented by the low er left and upper 
right boxes in Figure 2. If com parator therapies 
have the sam e e ffica cy  or e ffectiv en ess  and 
sam e price, then the ch o ice  is based on the deci­
sion  m akers’ preferences; no econ om ic analy­
sis is required to a ssist in  d ecision  m aking. 
H ow ever, w hen  a new  drug has higher e ffe c ­
tiveness than ex istin g  therapy and costs more, 
or vice-versa , a formal econ om ic analysis is 
warranted.
WHAT IS PHARMACOECONOMICS?
P harm acoeconom ics is  a decision-assisting  
tool w hich evaluates healthcare resources co n ­
sum ed to produce health and econ om ic out­
com es. V aluation o f  resources and outcom es  
fo llow s a three-step process:
• id entify  the relevant resources and out­
com es,
• m easure resources and outcom es using  
appropriate physical units, and
• com pare them.




(oi drug relative to the alternative)
Higher Equal Lower
Higher Yes No V No '
Equal No No No
Lower :: No Yes
Problem s m ay be encountered in all three 
phases. S om e item s are d ifficu lt to identify in  
health care interventions.
N ot all resources and ou tcom es can be m ea­
sured in appropriate physical units. For ex a m ­
ple, som e interventions have subjective ou t­
com es such  as the reduction o f  pain or increase  
in o n e ’s quality o f  life . T he identification  and 
m easurem ent o f  these resources and outcom es  
depend on the perspective o f  the study and tim e  
fram e used.
The perspective o f  the study d efines the 
view point form  w hich the study is undertaken.1 
A pharm acoeconom ic analysis can be c o n ­
ducted from  several perspectives, e .g ., that o f  
the provider, payer, patient or soc ie ty . T he  
study p erspective should be clearly  stated b e­
cause the perspective determ ines the relevance  
o f  costs and outcom es that need to be identified  
and valued. Study results w ill w idely  vary d e ­
pending on the perspective o f  the study. For e x ­
am ple, i f  you are considering a payer’s (such as 
the health plan) perspective, then resources and 
outcom es relevant to the health plan w ould  be 
identified, m easured, and com pared. R esources 
m ay include serv ices for w hich  the health plan  
parys for, e .g ., prescriptions, o ffice  v isits, lab 
tests. T he health plan w ould  be less concerned  
about h ow  soon  the patients feel better enabling  
them  to return to work, w hile  that consideration  
w ould  be o f  direct relevance to the patients’ e m ­
ployers, i.e ., it w ould  be their perspective  
Sim ilarly  the tim e period over w hich  a prod­
uct or service is evaluated is a lso  important and  
depends on the ep id em io log ica l or clin ica l e v i ­
dence o f  the healthcare serv ices being ev a lu ­
ated. A n exam ple o f  a short-term  tim e fram e 
analysis is the cost o f  using epidural analgesia  
in the postoperative period to m anage pain as­
sociated with orthopedic procedures. Another  
exam ple could  be use o f  serotonin  5 -H T -l an­
tagonists (triptans) to abort m igraine head­
aches. A  long-term  tim e fram e m ay be m ore  
relevant w hen one is evaluating preventive ser­
v ices  w ith w hich costs o f  the program m ay o c ­
cur n ow  but benefits or health outcom es attrib­
utable to the intervention m ay be seen  on ly  in 
the near or distant future. An exam ple o f  this 
longer tim e frame w ould  be use o f  interdisci­
Perspective and Time
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plinary care in m anaging patients w ith chronic 
nonm alignant pain. In this setting, a patient 
may not present with m axim al im provem ent 
until som e distant tim e. It is p ossib le  for major 
benefits associated  w ith the cost o f  type o f  care 
to occur after con clu sion  o f  interdisciplinary  
care. Thus depending on the clin ical relevance  
and the tim e availability  data, the m easurem ent 
o f  resources and outcom es m ay vary according  




R esources are alw ays valued in terms o f  
costs. Theoretically, econ om ists consider these  
costs to be the benefits o f  opportunities fore­
gon e (opportunity cost). B ecau se  opportunity  
costs are d ifficu lt to infer, researchers often  use  
reference prices or reim bursem ent rates to  
value resources. R eference prices are listprices  
that serve as references for particular products 
or services, w hereas reim bursem ent rates are 
the actual costs o f  a serv ices or goods. C osts can 
be divided into four categories: direct m edical 
costs; direct non-m edical costs; indirect costs; 
and intangible costs.
1. D irect m edical costs are costs  o f  m edical 
resources consum ed that are directly re­
lated to the m edical product or service  
being evaluated. For exam ple, copay  
am ount for a physician  v isit or ou t-o f­
pocket exp en ses when patients purchase 
prescription m edications.
2. D irect non-m edical co sts  are costs o f  
non-m edical resources consum ed as the 
result o f  providing or obtain ing the m ed i­
cal goods o r  services under evaluation. 
For exam ple, transportation costs to go  
and see your doctor.
3. Indirect costs are costs “indirectly” a sso ­
ciated with the consum ption o f  a m edical 
product or service under evaluation. For 
exam p le, peop le w ho are s ick  either don ’ t 
show  up at work (absenteeism ) or work at 
a lesser e ffic ien cy  (presenteeism ). From  
an em p loyer’s perspective the costs a sso ­
ciated w ith lost productivity w ould  be  
considered as an exam p le  o f  indirect cost.
4. Intangible costs are defined  as costs a sso ­
ciated w ith pain and suffering resulting  
from  a treatm ent or illn ess itself. There is 
som e debate am ong econ om ists as to 
. whether to include these as costs or value  
them as outcom es.
Examples o f  Data Sources 
to Measure Resources
V alues for resource inform ation can com e  
from  various sources and should a lw ays be 
valid and relevant to the pharm acoeconom ic  
study under consideration . Table 1 lists som e  
sources o f  reference prices or reim bursem ent 
rates. Rather than g o  into detail as to the various 
advantages and disadvantages o f  these data 
sources, it is su ffic ien t to Say that none o f  these  
is perfect; som e are very c lo se  to the true cost o f  
the m edical serv ice  or drug and som e a bit far­
ther aw ay. E ach data source com es with a tim e, 
and m oney constraint.
Valuation/Measurement o f  Outcomes
W hen id en tify in g  health or econ om ic  out­
com es, o n e  can ch o se  from  a list o f  ou tcom es. 
Broadly these ou tcom es are c la ssified  into 
three categories, i.e ., econ om ic , clin ica l, and 
hum anistic outcom es.
1. E conom ic ou tcom es are usually  valued  
in terms o f  co sts  or resource use o f  ser­
v ices or goods avoided  due to a treatment. 
For exam p le i f  an investigator w ishes to 
com pare sumatriptan and alm otriptan for 
m igraine headache m anagem ent, a p o ­
tential eco n o m ic  ou tcom e could  be the 
num ber o f  urgent v isits  or hosp italiza­
tions that persons taking the drugs experi - 
enced du e to chest pain, a com m on  
adverse even t o f  triptans. T he drug with  
the low er in cid en ce o f  this adverse out­
com e w ould  be considered superior in 
terms o f  an outcom e evaluation.
2. C linical ou tcom es include those that are 
generally reported in a clin ical trial or 
real-w orld clin ica l studies and may in­
clude the e ffica cy /e ffec tiv en ess  o f  a 
drug. T hese are the easiest to measure
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w ith the sim plest being m ortality. C lin i­
cal outcom es may include clin ical e ff i­
ca cy /e ffectiv en ess , re lie f or reduction in 
sym ptom s.
3. H um anistic outcom es include patient 
com pliance and quality o f l if e .  T hese are 
the m ost d ifficu lt to m easure. H ow ever, 
in chronic pain m anagem ent and pallia­
tive care, hum anistic outcom es are very  
important.
W hen sh ifting from quantitative to qualita­
tive ou tcom es, m easurem ent b ecom es a chal­
lenge. It is a lso  a challenge to identify the m ost 
relevant and desirable outcom es w hen com par­
ing therapies.
R eturning to the earlier exam ple o f  interdis­
ciplinary chronic nonm alignant pain m anage­
ment, what types o f  qualitative measures should  
be considered? In chronic nonm alignant pain it 
is necessary to consider the patient’s report o f  
pain intensity, psych o log ica l state, perceived  
and real functional ability, and overall enjoy­
ment o f  life . O ne m ethod to ach ieve this a ssess­
m ent is u se  o f  the Treatm ent O utcom es in Pain 
Survey (T O P S).2-3 T his fu lly  validated, chronic 
p ain -sp ecific  health-related quality o f  life  in­
strument provides for m easuring pain-related  
outcom es, across fourteen sca les as depicted in 
Table 2. T he sixty-item T O P S questionnaire in ­
cludes the full M edical O utcom es Study Short 
Form  36 (S F -36) and captures additional data 
on pain, functional lim itations, perceived and 
real fam ily /socia l disability, and formal work  
disability. A  unique feature o f  the TO PS is that 
it can be used to m easure individual patients
TABLE 1. Types of Resources
S ources E xam ples
Physician Fee Schedules Medicare Fee Schedule
Hospital Charges Hospital Claims Database
Insurance/Em ployer Claims State Medicaid; MedStat 
MarketScan Database
Average W hole-Sale Price (AWP) or 
W holesale Acquisition Cost (WAC) lor 
Drugs
Red Book or claims Irom 
a PBM
Electronic M edical Records Veterans Health 
Administration's Decision 
Support System (DSS)
National Surveys Medical Expenditure 
Panel Survey (MEPS)
H R Q oL over tim e, as wel l as serving as a useful 
research tool.4
Both careful exam ination and a good k n ow l­
ed ge o f  the c lin ica l ep id em io lo g y  o f  the thera­
p ies under study are essentia l in addition to the 
kinds o f  data that are available. It is usually ea s­
ier to find data on short-term  ou tcom es and 
harder for long term outcom es.
T he overall goal o f  any pharm aceutical in ­
tervention is theoretically to in fluence the long  
term outcom es such as decreased m orbidity  
and prolongation o f  life. T herefore, i f  one in ­
cludes only short term health ou tcom es due to 
tim e constraints one needs to assure that the 
short term outcom es correlate w ell w ith the 
long term outcom es.
W hen you do “som eth in g” to a human being, 
it m ay im pact h is/her health, esp ecia lly  i f  that 
“som ething” is a treatment. B efore attem pting  
to m easure the im pact o f  d isease  or therapy on 
health or changes in health, one m ust address 
the question o f  d efin in g  health.
A ccording to the 1948 W orld Health O rgani­
zation defin ition , health is a state o f  com plete  
physical, m ental, and social w ell-b ein g , and not 
m erely the absence o f  d isease or infirm ity.5 
W ith such a broad defin ition , m easurem ent o f  
health has traditionally focused  on the latter 
part o f  the defin ition , i.e ., the absence o f  d is­
ease. This is ev ident by the em phasis and im ­
portance o f  use o f  objective clin ical patient out­
com es such as laboratory values w ithin the 
m edical com m unity.
TABLE 2. Treatment Outcomes in Pain Survey 
(TOPS) Scales
Pain S ym ptom O b jec tive  W o rk  D is a b ility
Work Limitations Lower Body Functional Lim itations
Upper Body Functional 
Lim italions




Lite Control Passive Coping
Solicitous Response • Fear Avoidance
Satisfaction with Outcom es Healthcare Satisfaclion
HEALTH RELATED QUALITY 
OF LIFE (HRQOL)
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T he term ‘health-related quality o f  l ife ’ 
(H RQ oL) is often  applied to the im pact o f  d is­
ease and treatment on patients’ liv es . It is d is­
ease-sp ecific  w hereas quality o f  life  (Q oL ) is a 
concept w hich en com p asses an in d iv id u al’s 
perceived level o f  physical, p sych o log ica l, and 
social w ell-being . H R Q oL aim s to encom pass  
the entire construct o f  health and is defined as a 
person’s o ra  group’s subjective assessm ent o f  
their functioning and w ell-being . For that rea­
son it is  gaining great popularity as an outcom e  
m easure within the m edical com m unity. This 
popularity is evident with the increase in num ­
ber o f  publications in the literature in the past 
tw o decades.
In 1973 only  five articles listed  “quality o f  
life” as a reference keyw ord in the M E D L IN E  
database; this num ber grew  to 16 ,256  in 1998. 
Q uality o f  life  is now  recognized as important 
in the m anagem ent o f  chronic d iseases and is 
w idely  m onitored in chronically ill patients. It 
has also been used in evaluating treatment in 
clin ical trials, as w ell as in a llocating resources 
at the health p o licy  levels.
Measuring HRQOL
T ypically , H R Q oL m easurem ent is done  
through psychom etrically  validated question­
naires w hich are designed to assess patients’ 
perception o f  their illness, and its im pact on 
their lives. M easurem ent o f  H R Q oL usually  
en com passes three major dom ains.
1. Physical w ell-b ein g  (or status) w hich  
m easures how  an illness or your current 
health im pact the ind ividual’s activities 
o f  daily liv in g , e .g ., using the bathroom , 
clim bing stairs.
2 . Socia l/ro le  functioning is the dom ain  
w hich m easures how  o n e’s health or ill­
ness im pacts his/her ability to interact 
w ith others.
3. E m otional/psychological w ell-b ein g  or 
status m easures the im pact on mental 
health, e .g ., questions about how  stressed  
or nervous the subject has been, whether 
s/he has felt downhearted, and quantitates 
this construct.
tw o types o f  H R Q oL m easu res-gen eric  or d is­
ea se-sp ecific .
1. General m easures (e .g ., the M edical O ut­
com es Study [M O S] Short Form  36, 
S F -36) applicable across all d iseases, 
m edical interventions, and a w id e  variety  
o f  populations.
2. D isea se-S p ec ific  m easures (e .g ., A sthm a  
Q uality o f  L ife  Q uestionnaire) applica­
ble for sp ecific  conditions or d iagn oses.
T hese m easures co m e in tw o form ats, i.e ., 
profiles w hich are descriptive in nature and in­
d ices w hich m easure utility.
1. Health profile  H R Q oL  m easures repre­
sent independent d im ension  scores that 
are im portant and relevant to clin ician s  
w ho w ould  like to a ssess the e ffec t o f  a 
therapy on various d im en sion s o f  a p a­
tient’s H R Q oL  and thus better gu id in g  
patient care. An exam ple o f  health p rofile  
is the S F -36  w hich is represented by an 
array o f  scores for individual quality o f  
life  or health status d im ensions.
2. A  Health Index (e .g ., Q uality o f  w ell b e ­
ing scale, Health utility index, E uroQ ol 5 
D im ensional Format) is a sin g le , overall 
score ranging from zero to on e, repre­
senting the quality o f  life  associated  w ith  
death and perfect health, respectively .
a. T he advantage is that index scores can 
be used in more in-depth ou tcom e as­
sessm ent (e .g ., C ost U tility A n a lysis)
b. The d isadvantage is that it usually  
does not provide scores for individual 
dim ensions.
DISCOUNTING
a. T he advantage is that the health pro­
file  provides an outcom e score for 
individual d im ensions to a llow  for 
determ ination o f  d ifferential e ffect.
b. The d isadvantage is that one cannot 
aggregate across all d im en sion s for a 
com p osite  or unitary m easure o f  
health status or quality o f  life .
A few H R Q oL in stru m en tsa lsom easu red is- Inputs and con seq u en ces o f  a health inter­
ease- or treatment-related sym ptom s. There are vention accrue at different tim es, esp ec ia lly  for
constant to determ ine the in flu en ce on the 
end results.
2. M ulti-w ay S A  or threshold analysis  
w hereby tw o or more parameters are var­
ied sim ultaneously .
3. Probabilistic analyses are a type o f  S A  in 
w hich the probability o f  an uncertain pa­
ram eter is varied w ithin the sp ec ified  d is­
tribution o f  the uncertain parameter.
OVERVIEW  
OF PHARMACOECONOMIC  
METHODOLOGIES
chronic d isease and population-based programs 
developed  to deal with them. In such a case one  
cannot d irectly com pare the inputs o f  a program  
starting today with its con seq u en ces w hich w ill 
accrue in thirty years’ tim e.
E conom ists adjust the valuation o f  such co n ­
sequences to take account o f  the d ifference in 
tim e by using a technique called  d iscounting  
w hich a llow s the calculation o f  the present va l­
ues o f  inputs and benefits w hich  accrue in the 
future.
D iscounting  is prim arily based on selection  
o f  a preferred tim e, e .g ., individuals prefer to 
forego a part o fth e  benefits/paym ent if  they a c­
crue it now , rather than fully in the uncertain fu­
ture. The strength o f  this preference is e x ­
pressed by the discount rate w hich is inserted in 
econ om ic evaluations. T he ch o ice  o f  a d iscount 
rate and the ch o ice  o f  which item s it should be 
applied to are a matter o f  i ntense-debate am ong  
econ om ists.
Som e exam p les used are bank interest or 
m ortgage rates; inflation rate (e .g ., M edical 
C onsum er Price Index); or standard discount 
rate used in econ om ic  literature are used to ca l­
culate present values.
SENSITIVITY ANALYSIS (SA)
Parameters that go  into a pharm acoeco- 
nom ic m odel are usually estim ates o f  the true 
costs o f  outcom es. To deal with this uncer­
tainty, pharm acoeconom ic evaluations use a 
technique called sensitiv ity  analysis w hich re­
peats the com parison o f  alternatives by varying  
the estim ates w ithin a certain range to deter­
m ine how  it w ould  influence the end results.
Caution is needed when conducting a sen si­
tivity analysis (SA ) because estim ates may be 
guesses or m ay be associated with expert op in ­
ions or anecdotal evidence. There are areas o f  
m ethodologica l controversy (e .g ., d iscount 
rates) and one has to be careful w hen generaliz­
ing to other settings (e .g ., dem ographic differ­
ences).
There a num ber o f  different types o f  SA  
w hich include:
1. O ne w ay S A  or threshold analysis w here­
by, for exam ple, on ly  one parameter at a 
tim e is changed, holding everything e lse
B y defin ition  pharm acoeconom ic analyses  
are sim ply resource-outcom e analysis. R e­
sources are valued in terms o f  costs, and out­
com es or con seq u en ces o f  drug therapy are e i­
ther valued in terms o f  natural units or m onetary  
units. There are fiv e  general types o f  pharm a­
coecon om ic  analyses as described below .
C ost-M in im ization  A n alysis  (C M A ) values 
resources as costs and outcom es are assum ed to 
be identical. The goal o f  C M A  is to identify  the 
least ex p en siv e  alternative. R esu lts o f  a C M A  
analysis are expressed  in m onetary units, as 
only resources betw een  the alternatives are 
com pared. T heoretica lly , sin ce  no tw o inter­
ventions have the sam e exact c lin ica l out­
com es, C M A  is seldom  used. H ow ever, there 
are som e situations like com parisons o f  brand 
and generic versions o f  the sam e product, or 
com parisons o f  different routes o f  adm inistra­
tion o f  the sam e drug, w here C M A  could  be 
applied.
C ost-E ffectiven ess A n alysis  (C EA ) is the 
m ost w idely  used pharm acoeconom ic m ethod. 
Here resources are valued in m onetary units. 
O utcom es are valued in natural units such as 
years o f  life  saved, sym ptom  free days, percent 
low  density lipoprotein (LDL) reduction. There­
fore results are expressed  as cost per natural 
unit. In CEA alternatives that can be expressed  
in the sam e natural units are com pared. C on­
sider tw o anticonvulsants used to treat neuro­
Cost-Minimization Analysis
Cost-Effectiveness Analysis
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pathic pain. Both drugs may provide an average  
30% decrease i n patient-reported pain and have 
very sim ilar adverse effect profiles. In this e x ­
am ple drug A  is available generically  and at 
half the co st o f  the brand nam e on ly  drug B 
product. S in ce both drugs have the sam e out­
com e (i.e., 30%  pain reduction) drug A  is more 
cost-e ffective . H ow ever consider the situation  
w here there is a d ifference in pain reduction be­
tw een these drugs. For exam ple, drug A  de­
creases pain report by 25%  and drug by 35%. 
S in ce  the outcom e has changed, it is not p o ssi­
ble to conduct a co st e ffectiven ess analysis. A  
sim ilar dilem m a occurs when on e considers 
costs associated with adverse even ts and these  
costs differ betw een tw o therapies. In this situa­
tion a cost-e ffectiv en ess  analysis w ould be in­
appropriate. The C EA  can be presented as an 
average CE ratio via a formula,(the cost o f  ther­
apy/outcom e m easured in natural units), incre­
m ental CE ratio, and what the additional amount 
w ould need to be paid to obtain the additional 
effect. A dvantages o f  a C EA  is that it serves to 
com pare varied form s o f  therapy (e .g ., di fferent 
classes o f  drugs to treat the sam e d isease), phy­
sicians and payers find it useful and acceptable, 
and Intermediaries (short-term  outcom es) can  
be evaluated. A  disadvantage is that alterna­
tives must have sim ilar outcom es.
Cost-Utility Analysis
C ost-U tility  A n alysis (CU A ) by defin ition  is 
a form  o f  C EA  in w hich outcom es are adjusted 
for patient preferences (utility). U tility  is a co n ­
cept used by econ om ists to m easure satisfac­
tion or w ell-b ein g  and it form s the basis for 
m any m odels o f  consum er choice. C onsum ers 
w ill purchase good s that g ive  them  the greatest 
utility per dollar spent. C ost-utility  analysis at­
tem pts to m easure the utility derived from  
changes in health status and to calcu late the cost  
per unit o f  utility. The goal is to determ ine  
w hich alternative accom p lish es the g iven  ob­
jectiv e  at the least cost. In pbarm acoeconom ic  
evaluations, the m ost com m on m easure o f  util­
ity is the quality adjusted life  year, pronounced  
as Q A L Y . Q A LY : a unit o f  ou tcom e in w hich  
the quantity o f  life  (i.e ., survival) is adjusted for 
its quality (i.e ., functioning and w ell-being). 
T his com plicated m ethod developed  to: over­
com e the lim itations o f  a CEA m ethodology
w here com parisons o f  therapies had to be lim ­
ited to sim ilar outcom es; and to com pare  
interventions that affect not on ly  m ortality (i.e ., 
quantity o f  life) but also m orbidity (quality o f  
life ) -a  classic  exam p le  w ould  be palliative ch e­
m otherapy for term inally ill cancer patients. In 
this setting, one considers the co st o f  providing  
palliative chem otherapy in terms o f  what this 
provides to lengthen life  and w hatquality  o f  life  
is provided from  this intervention.
Cost-Benefit A nalysis
C ost-B en efit A n a lysis  (C B A ) com pares re­
sources and ou tcom es o f  a program or treat­
ment m easured in m onetary terms. T he charac­
teristics o f  C B A  allow  it to com pare alternatives 
with sim ilar and dissim ilar outcom es, resources 
and outcom es m easured in m onetary units, and 
results reported as net benefits (B -C ) and bene­
fit to cost ratio (B /C ). The ob jective  o f  a C B A  is 
to find the alternative with the greatest net bene­
fit; determ ine whether a good  or service has a 
p ositive net benefit. An advantages o f  C B A  is 
that it can com pare w ide-varying  program s and 
services, is easily  understood. A  d isadvantages 
o f  C B A  is that the valuation o f  outcom es in 
monetary term s can be challenging  and that it is 
not w idely  excepted  in healthcare environm ent.
Cost-Consequence Analysis
C ost-C onsequence A n alysis (C C A ) is a pre­
sentation o f  all costs (direct, indirect) and all 
outcom es (clin ica l, hum anistic, and econ om ic)  
in a tabular form  w ithout aggregating it into any 
form  o f  cost-ou tcom e ratio. T he characteristics 
o f  C C A  is that resources are m easured in m on e­
tary units, ou tcom es are m easured in m ultip le  
w ays, and results are presented in a tabular for­
mat. T he objective o f  C C A  is to assist d ecision  
makers for ch oosin g  the m ost relevant re- 
source-outcom e ratio. A n advantage o f  C C A  is 
that it is transparent, f lex ib le , conceptually  the 
sim plest, avoids controversies, and is the m ost 
com prehensive. A  d isadvantages o f  C C A  is 
that it is labor/resource intensive.
T able 3 sum m arizes the pharm acoeconom ic  
m ethodologies d iscu ssed  in this section.
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TABLE 3. Summary of Pharmacoeconomic 
Methods
Type of PE Analysis Resources Outcomes
Cost-m inim ization Monetary units Natural units
Cost-effectiveness Monetary units Natural units
Cost-utility M onetary units Quality-Adjusted Life Years
Cost-benefit Monetary units Monetary units
Cost-consequence Monetary units All o f the above
GENERAL STEPS IN DESIGNING A 
PHARMACOECONOMIC STUDY
A fter determ ining that a form al econom ic  
evaluation  is necessary, the investigator should  
com p lete  the fo llow in g  seven  steps to design  
and conduct the study.
1. D efin e  the problem  (e .g ., what is a cost-  
e ffec tiv e  w ay o f  m anaging hypertension  
in a defined population?). D efin ing  the 
problem  w ill help you determ ine the ap­
propriate pharm acoeconom ic m ethodol­
ogy  that you w ill need to use.
2. Identify alternative interventions (e .g ., 
pharm aceutical) w hich m ay include drug 
therapy w ith  A C E-inhibitors, and ca l­
cium  channel blockers, life-sty le  inter­
ventions m ay include diet and exercise .
3. Identify the perspective in terms o f  w hose  
v iew -poin t needs to be considered for this 
study.
4. Identify and m easure relevant resources 
and outcom es.
5. D iscount costs and outcom es if  they need  
to be.
6. Conduct a sensitiv ity  analysis to over a 
range o f  estim ates that you have assum ed  
or m easured to determ ine whether they 
are robust, m eaning do they change the 
study results i f  you vary them.
7. Report the pharm acoeconom ic results.
SUMMARY
D ue to the grow ing healthcare costs, d ec i­
sion-m akers in the healthcare market are be­
com ing increasingly cost-con sciou s and in­
creasingly  question the costs and value o f
healthcare interventions. P harm acoeconom ics  
evo lved  from such cost and value concerns and 
is an important tool that can assist d ec is io n ­
makers in optim izing healthcare resources. 
Pharm acoeconom ic analyses are indicated only  
w hen both cost and effect o f  the alternative  
therapy are higher or low er than standard treat­
ment. There is a lw ays the challenge to identify  
and assign  value to relevant resources. T his in ­
cludes both direct and indirect costs o f  e c o ­
nom ic, clin ica l and hum anistic outcom es.
H RQ oL is now  accepted  as an important 
type o f  outcom e in addition to clin ical ou t­
com es, e sp ec ia lly  in chronic d isease  co n d i­
tions. It is  a lso  becom ing a routine com ponent 
to assess quality o f  health care.
D iscounting  costs and outcom es to a present 
day value are important esp ecia lly  if  they are 
accrued over several years.
Investigators should  perform  sen sitiv ity  
analyses to understand how  changes in the 
m odel inputs influence the outputs.
And finally , depending on how  investigator  
frame the questions, they can use five  different 
pharmacoeconomic m ethods-C M A , CEA, C U A , 
C B A , and C C A  to determ ine the value o f  a 
pharm aceutical serv ice or therapy.
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